Brian Rini, MD, FASCO

Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.

Articles by Brian Rini, MD, FASCO

Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
View More
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Brian Rini, MD, FASCOASCO GU Symposium 2024 | January 30, 2024
Dr. Brian Rini discusses KEYNOTE-564 long-term survival data and LITESPARK-005 PROs.
Brian Rini, MD, FASCOUromigos Live 2023 | November 14, 2023
Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
Brian Rini, MD, FASCORoundtable | December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
Michael Morris, MDUromigos Live 2023 | November 8, 2023
Michael Morris, MD, discusses radioligand therapy for prostate cancer, including common practices and new data.
Monty Pal, MDUromigos Live 2023 | November 8, 2023
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Sam Chang, MDUromigos Live 2023 | November 6, 2023
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.